The scope of this review is to summarize approaches that direct target CD155 either as receptor for Poliovirus to address oncolytic virus action on cancerous cells or as a ligand for DNAM-1 and TIGIT immune receptors to favor a more efficient anti-cancer immune response. The gene discussed is CD226; the disease is cancer.